Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2022, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook.
FAP-2286
is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent
targeting fibroblast activation protein (FAP) to enter clinical development and
is the lead candidate in Clovis Oncology’s targeted radiotherapy (TRT)
development program. The Phase 1 portion of the LuMIERE study, for which
enrollment in the third of four planned dose cohorts is ongoing, is evaluating
the safety of the FAP-targeting investigational therapeutic agent and will
identify the recommended Phase 2 dose and schedule of lutetium-177 labeled
FAP-2286 (177Lu-FAP-2286). FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) is
being used as an investigational imaging agent to identify patients with
FAP-positive tumors appropriate for treatment in LuMIERE. Once the Phase 2 dose
is determined, Phase 2 expansion cohorts are planned in multiple tumor types
and are expected to initiate in the fourth quarter of 2022.
To
read more please visit:
Source:
Clovis